Diseases, CLL, Lymphoma (any), Therapies, Adverse Events, Biological Processes, Cell Lineage, Lymphoid Malignancies, Clinically relevant
John G. Gribben, MD, DSc, FRCP, FMedSci, FRCPath, Queen Mary University of London
Gribben: Janssen: Honoraria, Research Funding; AstraZeneca: Honoraria, Research Funding; TG Therapeutics: Consultancy, Honoraria; Morphosys: Honoraria; Novartis: Honoraria; Gilead: Honoraria; Celgene: Research Funding; Abbvie: Honoraria.
Philip A. Thompson, MB, MS, The University of Texas MD Anderson Cancer Center
Alessandra Tedeschi, MD, Niguarda Hospital
Ryan Jacobs, MD, Department of Hematology, Lymphoma Division, Assistant Professor of Medicine, Levine Cancer Institute/Atrium Health
Terry Evans, CLL Patient & Advocate
Thompson: Janssen-Cilag: Honoraria; Genentech: Consultancy; Pharmacyclics: Research Funding; Adaptive Biotechnologies: Consultancy, Research Funding; AbbVie: Research Funding. Tedeschi: Sunesis: Consultancy; Department of Hematology Niguarda Hospital Milano: Current Employment; Janssen spa: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Jacobs: TG Therapeutics, Inc.: Research Funding; Pharmacyclics: Research Funding, Speakers Bureau; AbbVie: Consultancy, Speakers Bureau; Astra Zeneca: Consultancy, Speakers Bureau; Seattle Genetics: Consultancy; Verastem: Consultancy; Janssen: Consultancy, Speakers Bureau; Genentech: Speakers Bureau; Sanofi Genzyme: Speakers Bureau.
This accredited CE activity has been developed in collaboration with CLL Society Inc.
The validation of innovative therapeutics for the treatment of chronic lymphocytic leukemia (CLL) has radically upended a decades-long consensus centered on chemotherapy-based treatment and provided clinicians and patients with a wide range of personalized treatment options. These highly active therapies, including BTK, PI3K, and BCL-2 inhibitors and next-generation antibodies, have opened the door to “uncharted medical territory,” where potent treatment, modern safety management strategies, and the potential for long-lasting, robust responses are redefining the approach to caring for CLL patients.
This “Seminars and Tumor Board” live web broadcast will pair compelling, real-world case scenarios with the practice-changing evidence that continues to support the increasing role in treatment for novel therapeutics in CLL. This event will also explore the future of CLL care and illustrate how novel combinations and cellular therapy may lead to deep, durable, and minimal residual disease–negative responses. Throughout, our expert panel will describe the challenges and milestones of the patient’s journey in order to illustrate the human face of the dramatic progress made in managing CLL in recent years. Register now to join the experts for this unique activity and learn how innovation is fueling changes in treatment for CLL.